Source: GlobalNewswire

Press Release: Replay : Replay's cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma

Replay's cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma

Read full article »
Replay's Competitors | Replay's News | Replay's Financials
Stay up-to-date with the latest news on Replay
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Lachlan MacKinnon's photo - Co-Founder & CEO of Replay

Co-Founder & CEO

Lachlan MacKinnon

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Replay